J
Janis Racevskis
Researcher at Albert Einstein College of Medicine
Publications - 24
Citations - 4333
Janis Racevskis is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Leukemia & Population. The author has an hindex of 16, co-authored 22 publications receiving 3674 citations. Previous affiliations of Janis Racevskis include New York Medical College & Montefiore Medical Center.
Papers
More filters
Journal ArticleDOI
Posttranscriptional regulation of the asialoglycoprotein receptor by cGMP.
TL;DR: Transblot analysis of HepG2 cell lysates indicated that the progressive loss in the steady-state level of asialoglycoprotein receptor (ASGR) when cells were maintained in medium supplemented with dialyzed fetal bovine serum was reversed by the addition of cell-permeant 8-bromo-cGMP.
Journal ArticleDOI
Differences in the abundance of variably spliced transcripts for the second asialoglycoprotein receptor polypeptide, H2, in normal and transformed human liver.
TL;DR: Poly(A+) RNA analysis of the normal liver and HepG2 cells by complementary RNA hybridization and ribonuclease protection corroborated the observations made during the screening of complementary DNA libraries regarding the abundance of the various messages.
Journal ArticleDOI
Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60
Farhad Ravandi,Megan Othus,Susan O'Brien,Stephen J. Forman,Chul S. Ha,Jeffrey Y.C. Wong,Martin S. Tallman,Elisabeth Paietta,Janis Racevskis,Geoffrey L. Uy,Uma Borate,Partow Kebriaei,Laura Kingsbury,Hagop M. Kantarjian,Jerald P. Radich,Harry P. Erba,Frederick R. Appelbaum +16 more
TL;DR: The addition of dasatinib to chemotherapy followed by an alloSCT in the eligible patients would lead to a significant improvement in relapse-free survival and the potential value of detection of minimal residual disease (MRD) using quantitative PCR for BCR-ABL fusion transcripts at defined intervals is examined.
Journal ArticleDOI
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
Muhamed Baljevic,Bogdan Dumitriu,Ju Whei Lee,Elisabeth Paietta,Peter H. Wiernik,Janis Racevskis,Christina Chen,Eytan M. Stein,Robert E. Gallagher,Jacob M. Rowe,Frederick R. Appelbaum,Bayard L. Powell,Richard A. Larson,Steven Coutre,Jeffrey E. Lancet,Mark R. Litzow,Selina M. Luger,Neal S. Young,Martin S. Tallman +18 more
TL;DR: Delta TL was found to be the most powerful predictor of overall survival when compared with well-established risk factors for poor outcomes in APL and shorter telomeres at diagnosis were significantly associated with high-risk disease.
Journal ArticleDOI
Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.
Dejan Juric,Norman J. Lacayo,Meghan Ramsey,Janis Racevskis,Peter H. Wiernik,Jacob M. Rowe,Anthony H. Goldstone,Peter J. O'Dwyer,Elisabeth Paietta,Branimir I. Sikic +9 more
TL;DR: DNA microarrays were used to identify gene expression profiles and molecular interaction networks related to BCR/ABL status and clinical outcome in a set of 54 adult ALL specimens from the MRC UKALL XII/ECOG E2993 intergroup study and constructed an indirect two-step labeling protocol based on signal amplification by use of dendrimer technology.